ACROSTUDY: The first 5 years

European Journal of Endocrinology

Volumn 161, Issue SUPPL. 1, 2009, Pages

  Trainer, Peter J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE RECEPTOR; HORMONE ANTAGONIST; HUMAN GROWTH HORMONE;

ACROMEGALY; ADRENAL INSUFFICIENCY; ADULT; ARTERY THROMBOSIS; ARTICLE; CEREBELLUM TUMOR; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPILEPSY; FACIAL NERVE PARALYSIS; FECES IMPACTION; FEMALE; FOLLICLE CYST; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; KNEE DISEASE; LABORATORY TEST; LEG THROMBOSIS; LIVER FUNCTION TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME; VERTIGO; ADOLESCENT; BLOOD; DRUG ANTAGONISM; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; REGISTER;

ACROMEGALY; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HEMOGLOBIN A, GLYCOSYLATED; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN; REGISTRIES; YOUNG ADULT;

EID: 70449877776     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0322     Document Type: Article

References (24)

1. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 20 1171-1177. (Pubitemid 30211048)
2. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (Pubitemid 33152999)
3. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z & Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology and Metabolism 2001 86 3304-3310. (Pubitemid 32673502)
4. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ & Gagel RF. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008 159 517-523.
5. Feenstra J, van Aken MO, de Herder WW, Feelders RA & van der Lely AJ. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology 2006 154 805-806. (Pubitemid 43997717)
6. Bernabeu I, Cameselle-Teijeiro J, Casanueva F & Marazuela M. Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. European Journal of Endocrinology 2009 160 869-872.
7. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ & German Pegvisomant Investigators. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology 2006 154 213-220. (Pubitemid 43308822)
8. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ & the German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82. (Pubitemid 46553905)
9. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK, Saller B & German Pegvisomant Investigators. Experience from the German pegvisomant observational study. Hormone Research 2007 68 70-73.
10. Brue T. ACROSTUDY: status update on 469 patients. Hormone Research 2009 71 34-38.
11. Bidlingmaier M. Pitfalls of insulin-like growth factor I assays. Hormone Research 2009 71 30-33.
12. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology andMetabolism 1998 83 3419-3426. (Pubitemid 28500866)
13. Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674.
14. Higham CE, Thomas J, Bidlingmaier M, Drake WM & Trainer PJ. Successful use of weekly pegvisomant administration in patients with acromegaly. European Journal of Endocrinology 2009 161 21-25.
15. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
16. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de HerderWW & van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogues and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.
17. Trainer PJ, Ezzat S, D'Souza GA, Layton G & Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clinical Endocrinology, 2009. In Press DOI: 10.1111/j.1365-2265. 2009.03620.x.
18. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691. (Pubitemid 41415476)
19. Rose DR & Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth hormone and IGF Research 2002 12 418-424. (Pubitemid 35378831)
20. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology 2003 149 521-527.
21. Paisley AN, Roberts ME & Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clinical Endocrinology 2007 66 723-726.
22. Maffei P, Martini C, Pagano C, Sicolo N & Corbetti F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Annals of Internal Medicine 2006 145 310-312. (Pubitemid 46768619)
23. Marazuela M, Daudén E, Ocón E, Moure D & Nattero L. Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Annals of Internal Medicine 2007 147 741-743. (Pubitemid 351664476)
24. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J & Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008 93 3515-3518.